GET DAILY SIGNALSWhy Is Myriad Genetics (MYGN) Stock Up +37.53% Today?
Key Takeaways
- Myriad Genetics (MYGN) surged approximately 37.53% on Tuesday, with shares trading near $5.79, up from a prior close of $4.21.
- The primary catalyst was a definitive agreement to sell its Prenatal Health testing business to Labcorp (LH) for $210 million in cash, plus inventory value at closing.
- Piper Sandler upgraded the stock to Neutral from Underweight and raised its price target to $5 from $2, citing reduced financial risk from the divestiture.
- Trading volume surged to roughly 15.5 million shares, well above the roughly 1.8 million average, signaling heavy investor interest.
- Traders are now watching for the company's third-quarter earnings call on November 4, 2026 and further details on the transaction.
Opening Summary
MYGN — Myriad Genetics, Inc., a genetic-testing and precision-medicine company focused on oncology, women's health, and mental health diagnostics — delivered one of the standout single-session moves in the market on Tuesday. The stock jumped about 37.53%, climbing to approximately $5.79 from a prior closing level of $4.21. The rally was driven by news that the company agreed to sell its Prenatal Health testing business to Labcorp for $210 million in cash, a deal investors read as a decisive step toward sharpening Myriad's focus and strengthening its balance sheet.
The Labcorp Divestiture: A Transformative Deal
The dominant catalyst behind the price rally was Myriad's announcement that it will divest its Prenatal Health segment to LH (Labcorp Holdings Inc.) for $210 million in cash, plus the value of inventory at closing. The portfolio being sold includes the Prequel, Foresight, SneakPeek, and FirstGene tests — a franchise that generated approximately $160 million in revenue over the trailing twelve months and served more than 600,000 patients.
The market reaction reflects a clear strategic rationale. Myriad's management said the transaction is expected to be accretive to revenue growth and profitability, while strengthening the balance sheet to support investment in the company's strategic priorities across the cancer-care continuum. For a business that has struggled with declining prenatal testing volumes and reimbursement pressure, offloading the segment is being viewed as a move that simplifies the company, reduces financial risk, and refocuses resources on higher-growth oncology and mental-health franchises.
Analyst Reaction: Piper Sandler Upgrade
The divestiture also triggered a notable shift in analyst sentiment. Piper Sandler upgraded Myriad Genetics to Neutral from Underweight, lifting its price target to $5 from $2. The firm pointed to the transaction as alleviating much of the financial risk that had previously underpinned its cautious stance, while also giving Myriad a "more focused" operating profile.
The upgrade carried added weight because Myriad's fundamentals had been under pressure in recent quarters. The company had missed earnings and revenue estimates, and its prenatal segment had been a persistent drag on overall testing volumes. By removing that overhang, the sale effectively reset how investors and analysts are valuing the remaining business, contributing to the outsized one-day move.
Market Context and Trading Activity
The earnings-driven-style surge was accompanied by dramatically elevated trading activity. Myriad shares traded roughly 15.5 million shares during the session, compared with an average of about 1.8 million — a multiple-times increase that underscored the conviction behind the move. Options activity also spiked, with call volume rising sharply relative to normal levels as traders positioned for further upside.
The rally was fundamentally company-specific rather than a broad-market or sector-driven event. The stock gapped up at the open and held its gains, breaking above its 50-day and 200-day moving averages, which sit well below the session's traded levels. The move reflected a re-rating of the shares tied to the strategic announcement and the accompanying analyst upgrade, rather than a lift from the broader biotech complex.
What Comes Next for MYGN
Investor attention now turns to execution and communication. Myriad is scheduled to provide further commentary on the transaction and related organizational changes on its third-quarter earnings call on November 4, 2026. Analysts and shareholders will be looking for clarity on how the divestiture reshapes the company's revenue trajectory, margins, and path toward profitability, as well as any details on the expected use of proceeds.
The deal is still subject to regulatory clearance and customary closing conditions, with completion expected by early 2027. Key risks include the possibility of delays in closing, integration assumptions, and the challenge of returning the remaining businesses to sustained growth. With analyst sentiment still broadly cautious despite the upgrade, the durability of the rally will likely depend on whether Myriad can translate its sharper strategic focus into consistent operational improvement.
Trending AI Robots
Tickeron's Trending AI Robots page showcases the platform's strongest-performing automated trading strategies under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and the symbols they trade. Only the top performers are featured in this curated section, giving traders a way to explore AI-driven approaches to stocks like MYGN. Explore the Trending AI Robots to discover which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
MYGN in +6.04% Uptrend, rising for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MYGN advanced for three days, in 201 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Aroon Indicator entered an Uptrend today. In 103 of 160 cases where MYGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for MYGN moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 22 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MYGN as a result. In 76 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for MYGN turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 32 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MYGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
MYGN broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. MYGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.863) is normal, around the industry mean (67.298). P/E Ratio (-5.017) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (1.236) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.448) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MYGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic and predictive medicine products
Industry MedicalSpecialties
Advertisement